Lipidio Pharmaceuticals
William D Humphries has more than 30 years of experience building and leading commercial-stage pharmaceutical organizations. Currently, Bill is the CEO Officer of Isosceles Pharmaceuticals, a position he has held since May 2021. Prior to his role at Isosceles, he served as President and Group Company Chairman, Ortho Dermatologics of Bausch Health Companies, as well the President and CEO of the North American business of Merz, an affiliate of Merz Pharma Group. Before joining Merz, he served in a number of leadership positions with Stiefel Laboratories, including as its Chief Commercial Officer and President, through their acquisition by GlaxoSmithKline. Prior to Stiefel, he was the VP of Allergan’s U.S. skincare business.
In addition, Bill currently serves as the Chairman of the board for both Clearside Biomedical and STRATA Skin Sciences, and as a Director for both Aclaris Therapeutics and PhaseBio. He received a BA from Bucknell University and an MBA from Pepperdine University.
This person is not in any offices
Lipidio Pharmaceuticals
Lipidio Pharma is focused on advancing a molecule to treat multiple dermatological diseases, including acne and sebaceous hyperplasia, as well as certain metabolic diseases such as nonalcoholic steatohepatitis (NASH) and obesity, which represent major unmet medical needs.